No Data
No Data
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)
Promising Potential of Corbus Pharmaceuticals' CRB-701 in Oncology: A Strong Buy Rating by Andrew Fein
Cannabis Stock Movers For February 17, 2025
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $42
Unlock the Full List
J L 7 2 : Now even good news is of no use, the stock price is plummeting
.